Heart Tronics, Inc. (HRTT)
Studio City, CA, US
Heart Tronics, Inc., established in 1987 and headquartered in Studio City, California, is a medical technology company specializing in the research, development, and marketing of medical devices across the United States. These devices are designed to track and quantify biological signals, aiding in the identification of illnesses that affect an individual's well-being. Among its current offerings is the Fidelity 100 Monitor System, an integrated solution where its Model 100 Patient Module gathers, processes, and enhances electrocardiogram (ECG) data from a patient via ten electrodes, transmitting this information wirelessly to a laptop computer. Currently in development are several innovative products. The Fidelity 350 Holter Monitor is a portable device crafted to collect continuous ECG data for conditions like arrhythmia and fleeting heart diseases, allowing patients to maintain their normal routines outside of clinical settings. Another developmental product is the Fidelity 200 Event Recording System/Heart Tempo Card, an over-the-counter heart monitoring device intended for proactive detection by individuals who wish to keep an eye on their cardiac health. The company also produces the Cardiac Vest, a snug-fitting, flexible vest or undergarment where electrodes are integrated directly into the fabric. Additionally, the Fidelity 400 Intracardiac Monitor utilizes Heart Tronics' unique signal acquisition and amplification technology to interpret intracardiac signals obtained from a catheter inserted within the heart. The company, formerly known as Signalife, Inc., rebranded as Heart Tronics, Inc. in November 2008.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -30.00% | -99.19% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-100.0%
-
EPS growth Medical - Devices: +28.5%-8.4% Q3'08: -93.7% (vs Q3'07)
-
FCF margin FCF growth · Medical - Devices: +30.9%—
-
EBIT margin Medical - Devices: +6.2%—
-
ROIC Medical - Devices: +3.3%-461.7% Q3'08: -1,193.1% (vs Q3'07)
-
Share dilution Medical - Devices: 0.0%+21.9% Q3'08: +40.4% (vs Q3'07)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.01× Q3'08: 0.02× (vs Q3'07)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2008 actual |
Dec 2009 actual |
|---|---|---|
| Revenue |
—
est.
|
1.62M
est.
|
| EBITDA |
—
est.
|
972.0K
est.
|
| EBIT |
—
est.
|
972.0K
est.
|
| Net Income |
—
est.
|
—
est.
|
| SGA |
—
est.
|
5.89M
est.
|
| EPS |
—
est.
|
—
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Budimir S. Drakulic | Chief Scientist, Vice President and Director of Research & Development | 233.0K | — |
| Rowland Perkins | Chief Administrative Officer and Director | 18.0K | male |
| Claire Mouton LaFrance | Director of Marketing and Communications | — | female |
| James J. Mazeika | Director of Business Development | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HRTT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
